References
- Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306–14; discussion 14–5.
- Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009;103:202–9.
- Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760–6.
- Reeves P, Irwin D, Kelleher C, Milsom I, Kopp Z, Calvert N, The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006;50:1050–7.
- Abrams P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006;25:293–4.
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002;187:116–26.
- Wyman JF, Harkins SW, Fantl JA. Psychosocial impact of urinary incontinence in the community-dwelling population. J Am Geriatr Soc 1990;38:282–8.
- Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology 2001;57:1044–50.
- Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6:S580–90.
- Herzog AR, Diokno AC, Fultz NH. Urinary incontinence: medical and psychosocial aspects. Annu Rev Gerontol Geriatr 1989;9:74–119.
- Hunskaar S, Vinsnes A. The quality of life in women with urinary incontinence as measured by the sickness impact profile. J Am Geriatr Soc 1991;39:378–82.
- Herzog AR, Fultz NH, Normolle DP, Brock BM, Diokno AC. Methods used to manage urinary incontinence by older adults in the community. J Am Geriatr Soc 1989;37:339–47.
- Peake S, Manderson L, Potts H. “Part and parcel of being a woman”: female urinary incontinence and constructions of control. Med Anthropol Q 1999;13:267–85.
- Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008;9:1787–96.
- Nilvebrant L, Hallen B, Larsson G. Tolterodine – a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997;60:1129–36.
- Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother 2001;2:1685–701.
- Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5–26.
- Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563–74.
- Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 2005;14:849–55.
- Coyne KS, Margolis MK, Thompson C, Kopp Z. Psychometric equivalence of the OAB-q in Danish, German, Polish, Swedish, and Turkish. Value Health 2008.
- Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997;104:988–93.
- Cisternas M, Noe L, Patel B, Remigio B, Williamson T, Black L. Comparison of persistence among therapies for overactive bladder: a retrospective pharmacy claims analysis. Neurourol Urodyn 2005;24:580.
- Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002;24:616–28.
- Appell RA, Abrams P, Drutz HP, Van Kerrebroeck PE, Millard R, Wein A. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001;19:141–7.